Development and in vitro Profiling of Dual FXR/LTA4H Modulators
Related Experiment Video
Updated: Aug 3, 2026
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Simone Schierle1, Steffen Brunst1, Moritz Helmstädter1
1Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438, Frankfurt, Germany.
Abstract:
Designed polypharmacology presents as an attractive strategy to increase therapeutic efficacy in multi-factorial diseases by a directed modulation of multiple involved targets with a single molecule. Such an approach appears particularly suitable in non-alcoholic steatohepatitis (NASH) which involves hepatic steatosis, inflammation and fibrosis as pathological hallmarks. Among various potential pharmacodynamic mechanisms, activation of the farnesoid X receptor (FXRa) and inhibition of leukotriene A4 hydrolase (LTA4Hi) hold promise to counteract NASH according to preclinical and clinical observations. We have developed dual FXR/LTA4H modulators as pharmacological tools, enabling evaluation of this polypharmacology concept to treat NASH and related pathologies. The optimized FXRa/LTA4Hi exhibits well-balanced dual activity on the intended targets with sub-micromolar potency and is highly selective over related nuclear receptors and enzymes rendering it suitable as tool to probe synergies of dual FXR/LTA4H targeting.
Insights
This study developed a dual-acting molecule to target both farnesoid X receptor (FXR) and leukotriene A4 hydrolase (LTA4H) for treating non-alcoholic steatohepatitis (NASH). This polypharmacology approach offers a promising strategy for this complex liver disease.
Area of Science:
- Pharmacology
- Hepatology
- Drug Discovery
Background:
- Non-alcoholic steatohepatitis (NASH) is a complex liver disease characterized by steatosis, inflammation, and fibrosis.
- Targeting multiple pathways simultaneously (polypharmacology) is a promising strategy for multifactorial diseases like NASH.
- Activation of farnesoid X receptor (FXR) and inhibition of leukotriene A4 hydrolase (LTA4H) are identified as key mechanisms to counteract NASH.
Purpose of the Study:
- To develop and evaluate dual FXR/LTA4H modulators as pharmacological tools for NASH treatment.
- To assess the potential of polypharmacology in addressing the multifaceted pathology of NASH.
- To create a well-balanced dual-acting molecule for probing therapeutic synergies.
Main Methods:
- Design and synthesis of dual polypharmacology agents targeting FXR and LTA4H.
- In vitro evaluation of compound activity, potency, and selectivity against intended and off-target molecules.
- Assessment of dual FXR/LTA4H modulators as tools for studying NASH pathogenesis and treatment.
Main Results:
- Development of optimized dual FXR/LTA4H modulators with sub-micromolar potency.
- Demonstration of well-balanced dual activity on both FXR and LTA4H targets.
- High selectivity of the developed compounds over related nuclear receptors and enzymes.
Conclusions:
- Dual modulation of FXR and LTA4H represents a viable polypharmacology strategy for NASH.
- The developed dual FXR/LTA4H modulators are suitable pharmacological tools for further investigation.
- This approach holds potential for developing novel therapeutics for non-alcoholic steatohepatitis.
More Related Videos
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
